Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04080180 · ClinicalTrials.gov registry record · NA
SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence
A NA study of Opioid Use Disorder, sponsored by Karen Derefinko, PhD.
- Completed
- Registry status
- NA
- Development phase
- 332
- Enrollment target
- 1
- Study location
NCT04080180: Completed NA study of Opioid Use Disorder, sponsored by Karen Derefinko, PhD.
NCT04080180 is a NA study of Opioid Use Disorder that has completed, run by Karen Derefinko, PhD. The registered enrollment target is 332 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04080180, a NA study of Opioid Use Disorder, has completed, sponsored by Karen Derefinko, PhD.
- COMPLETED
- Registry status
- NA
- Development phase
- 332 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the effectiveness of two different interventions for medication-assisted treatment (MAT) adherence: Contingency Management (CM) and Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM).
Primary Outcome
Number of visits where participant attends physician appointment and drug screen results are buprenorphine-positive.
Conditions Studied
Interventions
- BEHAVIORAL Contingency Management
- BEHAVIORAL Brief Motivational Interviewing + Substance Free Activities + Mindfulness
Study Locations (1)
Tennessee
- University of Tennessee Health Science Center - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2025-02-01 |
| Phase | NA |
What the finished NCT04080180 record still lists
NCT04080180 is an interventional study that assigns participants to a tested intervention. The registered 332 participants enrollment target is mid-sized for trials with a published cap, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Contingency Management is the first listed.
NCT04080180 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT04080180 about?
NCT04080180 is a clinical study titled "SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence". The purpose of this study is to compare the effectiveness of two different interventions for medication-assisted treatment (MAT) adherence: Contingency Management (CM) and Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM).
What is the current status of trial NCT04080180?
This trial is currently completed. It is a NA study. The enrollment target is 332 participants. The study started on 2022-02-01. Estimated completion is 2025-02-01.
What conditions does trial NCT04080180 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT04080180?
The interventions under investigation include: Contingency Management (BEHAVIORAL), Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BEHAVIORAL).
Who is sponsoring clinical trial NCT04080180?
This trial is sponsored by Karen Derefinko, PhD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04080180 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04080180's enrollment target sits among peer trials
332 52nd of 257 higher than 206 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
RECRUITING · NA
-
Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD
RECRUITING · NA
-
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
RECRUITING · NA
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
Using Facebook to Support Opioid Recovery Among American Indian Women
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174121 · 332 participants · Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- NCT02605785 · 332 participants · NA
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
- NCT04894006 · 332 participants · NA
Dementia Family Caregiver Study
- NCT05130606 · 332 participants · NA
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI